• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

癌症比例和其他用于区分恶性和非恶性胸腔积液的新参数。

Cancer ratio and other new parameters for differentiation between malignant and nonmalignant pleural effusions.

出版信息

Pol Arch Intern Med. 2018 Jun 30;128(6):354-361. doi: 10.20452/pamw.4278. Epub 2018 Jun 5.

DOI:10.20452/pamw.4278
PMID:29968696
Abstract

Introduction In contrast to tuberculous pleurisy (TP), no accurate and commonly accepted biochemical marker of malignant pleural effusion (MPE) has been established. Objectives We aimed to evaluate the ability of a previously reported cancer ratio (CR) to discriminate between MPEs and non-MPEs; to test whether age may have additional value in differentiating MPEs from non-MPEs; and if so, to combine lactate dehydrogenase (LDH) and age with other TP biomarkers in search of an index useful in the identification of MPEs. Patients and methods A retrospective analysis of data from 140 patients with malignant (n = 74), tuberculous (n = 37), and parapneumonic (n = 29) pleural effusions was performed. The diagnostic performance of a test to discriminate between MPEs and non-MPEs was evaluated using the receiver operating characteristic curve analysis. Results Three ratios showed the largest area under the curve (AUC): serum LDH to pleural fluid soluble Fas ligand, age to pleural fluid adenosine deaminase (ADA), and serum LDH to pleural fluid interleukin 18; moreover, the ratios were characterized by high sensitivity (95%, 93.2%, and 92.9%, respectively) and fair specificity (64.8%, 71.2%, and 58.5%, respectively) for differentiating MPEs from non-MPEs. The AUC for CR was lower and showed a sensitivity of 94.6% and a specificity of 68.2%. Conclusions Our study showed a lower specificity of the CR for discriminating between MPEs and non-MPEs than previously reported. We demonstrated that the combinations of serum LDH with other pleural fluid biomarkers of TP have a similar diagnostic performance. We also found that age might be an important factor differentiating between MPEs and non-MPEs and proposed a new age to pleural fluid ADA ratio which has a discriminative potential similar to that of the CR.

摘要

介绍

与结核性胸膜炎(TP)不同,尚未建立恶性胸腔积液(MPE)的准确且普遍接受的生化标志物。

目的

我们旨在评估先前报道的癌症比率(CR)区分 MPE 和非 MPE 的能力;检验年龄是否在区分 MPE 和非 MPE 方面具有额外价值;如果是,将乳酸脱氢酶(LDH)和年龄与其他 TP 生物标志物结合起来,寻找一种有助于识别 MPE 的指数。

患者和方法

对 140 例恶性(n=74)、结核性(n=37)和类肺炎性(n=29)胸腔积液患者的数据进行回顾性分析。使用受试者工作特征曲线分析评估用于区分 MPE 和非 MPE 的检验的诊断性能。

结果

三个比率的曲线下面积(AUC)最大:血清 LDH 与胸腔液可溶性 Fas 配体、年龄与胸腔液腺苷脱氨酶(ADA)、血清 LDH 与胸腔液白细胞介素 18;此外,这些比率在区分 MPE 和非 MPE 方面具有高灵敏度(95%、93.2%和 92.9%)和中等特异性(64.8%、71.2%和 58.5%)。CR 的 AUC 较低,灵敏度为 94.6%,特异性为 68.2%。

结论

我们的研究表明,CR 区分 MPE 和非 MPE 的特异性低于先前报道。我们证明了血清 LDH 与其他 TP 胸腔液生物标志物的组合具有相似的诊断性能。我们还发现年龄可能是区分 MPE 和非 MPE 的重要因素,并提出了一种新的年龄与胸腔液 ADA 比率,其具有与 CR 相似的鉴别潜力。

相似文献

1
Cancer ratio and other new parameters for differentiation between malignant and nonmalignant pleural effusions.癌症比例和其他用于区分恶性和非恶性胸腔积液的新参数。
Pol Arch Intern Med. 2018 Jun 30;128(6):354-361. doi: 10.20452/pamw.4278. Epub 2018 Jun 5.
2
Procalcitonin as a diagnostic marker in differentiating parapneumonic effusion from tuberculous pleurisy or malignant effusion.降钙素原作为鉴别脓胸性胸腔积液与结核性胸膜炎或恶性胸腔积液的诊断标志物。
Clin Biochem. 2013 Oct;46(15):1484-8. doi: 10.1016/j.clinbiochem.2013.03.018. Epub 2013 Apr 6.
3
Diagnostic Value of Vascular Endothelial Growth Factor, Transforming Growth Factor-β, Interleukin-8, and the Ratio of Lactate Dehydrogenase to Adenosine Deaminase in Pleural Effusion.胸腔积液中血管内皮生长因子、转化生长因子-β、白细胞介素-8 和乳酸脱氢酶与腺苷脱氨酶比值的诊断价值。
Lung. 2018 Apr;196(2):249-254. doi: 10.1007/s00408-018-0090-1. Epub 2018 Jan 20.
4
The pleural fluid lactate dehydrogenase/adenosine deaminase ratio differentiates between tuberculous and parapneumonic pleural effusions.胸腔积液乳酸脱氢酶/腺苷脱氨酶比值可区分结核性和类肺炎性胸腔积液。
BMC Pulm Med. 2017 Dec 4;17(1):168. doi: 10.1186/s12890-017-0526-z.
5
Clinical significance of pleural fluid lactate dehydrogenase/adenosine deaminase ratio in the diagnosis of tuberculous pleural effusion.胸腔积液乳酸脱氢酶/腺苷脱氨酶比值对结核性胸腔积液诊断的临床意义。
BMC Pulm Med. 2024 May 15;24(1):241. doi: 10.1186/s12890-024-03055-0.
6
Adenosine deaminase-based measurement in the differential diagnosis of pleural effusion: a multicenter retrospective study.基于腺苷脱氨酶的胸腔积液鉴别诊断测量:一项多中心回顾性研究。
Ther Adv Respir Dis. 2023 Jan-Dec;17:17534666231155747. doi: 10.1177/17534666231155747.
7
Laboratory and radiological discrimination between tuberculous and malignant pleural effusions with high adenosine deaminase levels.腺苷脱氨酶水平高的结核性与恶性胸腔积液的实验室及影像学鉴别
Korean J Intern Med. 2022 Jan;37(1):137-145. doi: 10.3904/kjim.2020.246. Epub 2021 Jul 15.
8
The role of pleural fluid lactate dehydrogenase-to-adenosine deaminase ratio in differentiating the etiology of pleural effusions.胸腔积液乳酸脱氢酶-腺苷脱氨酶比值在鉴别胸腔积液病因中的作用。
Chin J Physiol. 2022 May-Jun;65(3):105-108. doi: 10.4103/cjp.cjp_104_21.
9
Differentiating tuberculous from malignant pleural effusions: a scoring model.鉴别结核性与恶性胸腔积液:一种评分模型。
Med Sci Monit. 2003 May;9(5):CR175-80.
10
Adenosine deaminase (ADA) isoenzyme analysis in pleural effusions: diagnostic role, and relevance to the origin of increased ADA in tuberculous pleurisy.胸腔积液中腺苷脱氨酶(ADA)同工酶分析:诊断作用及与结核性胸膜炎中ADA升高来源的相关性
Eur Respir J. 1996 Apr;9(4):747-51. doi: 10.1183/09031936.96.09040747.

引用本文的文献

1
Age affects the diagnostic accuracy of the cancer ratio for malignant pleural effusion.年龄会影响恶性胸腔积液中癌比率的诊断准确性。
BMC Pulm Med. 2023 Jun 7;23(1):198. doi: 10.1186/s12890-023-02475-8.
2
Value of Cancer Ratio plus and Cancer Ratio Formulation in Distinguishing Malignant Pleural Effusion from Tuberculosis and Parapneumonic Effusion.癌症比率加值和癌症比率公式在鉴别恶性胸腔积液与结核性及肺炎旁胸腔积液中的价值
Tanaffos. 2021 Mar;20(3):221-231.
3
Developing a Prediction Score for the Diagnosis of Malignant Pleural Effusion: MPE Score.
开发一种用于恶性胸腔积液诊断的预测评分:MPE 评分。
Asian Pac J Cancer Prev. 2022 Jan 1;23(1):25-31. doi: 10.31557/APJCP.2022.23.1.25.
4
Role of cancer ratio and other new parameters in the differential diagnosis of malignant pleural effusion.癌症比率及其他新参数在恶性胸腔积液鉴别诊断中的作用
Clinics (Sao Paulo). 2021 Apr 26;76:e2515. doi: 10.6061/clinics/2021/e2515. eCollection 2021.
5
Pleural biomarkers in diagnostics of malignant pleural effusion: a narrative review.恶性胸腔积液诊断中的胸膜生物标志物:一项叙述性综述
Transl Lung Cancer Res. 2021 Mar;10(3):1557-1570. doi: 10.21037/tlcr-20-1111.
6
Diagnostic accuracy of the cancer ratio for the prediction of malignant pleural effusion: evidence from a validation study and meta-analysis.癌症比例对恶性胸腔积液预测的诊断准确性:来自验证研究和荟萃分析的证据。
Ann Med. 2021 Dec;53(1):558-566. doi: 10.1080/07853890.2021.1906943.
7
Diagnostic accuracy of cancer ratio for malignant pleural effusion: a systematic review and meta-analysis.恶性胸腔积液癌症比例的诊断准确性:一项系统评价和荟萃分析。
Ann Transl Med. 2019 Oct;7(20):554. doi: 10.21037/atm.2019.09.85.